Dec 30, 2025 • 富途牛牛
BEARISH
Roivant Sciences(ROIV.US) Officer Sells US$9.12 Million in Common Stock
An officer at Roivant Sciences (ROIV.US), Pulik Richard, sold 406.73K shares of common stock for a total of $9.12 million on December 23, 2025. This transaction was executed at an average price of $22.43 per share. The sale reflects a significant insider transaction, which is required to be reported under federal securities laws.
Dec 30, 2025 • MarketBeat
NEUTRAL
Richard Pulik Sells 406,731 Shares of Roivant Sciences (NASDAQ:ROIV) Stock
Richard Pulik, CFO of Roivant Sciences (NASDAQ:ROIV), sold 406,731 shares of the company's stock on December 23rd at an average price of $22.43, totaling over $9.1 million. This transaction decreased his holding by nearly 63%, leaving him with 239,413 shares. The company stock currently trades around $21.70, with recent analyst ratings suggesting a "Moderate Buy" consensus and an average target price of $25.19.
Dec 30, 2025 • MarketBeat
SOMEWHAT-BEARISH
Insider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 75,000 Shares of Stock
Roivant Sciences CEO Eric Venker sold 75,000 shares of the company's stock on December 24th for $1.69 million, bringing his total sales since October to approximately 1.96 million shares worth $36 million. This recent transaction decreased his ownership by 4.34%, though he still holds a significant stake. The company currently has a "Moderate Buy" consensus rating from analysts with an average price target of $25.19.
Dec 28, 2025 • MarketBeat
NEUTRAL
Capricorn Fund Managers Ltd Buys New Stake in Roivant Sciences Ltd. $ROIV
Capricorn Fund Managers Ltd initiated a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the third quarter, acquiring 198,500 shares valued at approximately $3.0 million. This comes as institutional investors now hold 64.76% of the company's stock, despite significant insider selling by CEO Matthew Gline and Director Daniel Allen Gold totaling over $55 million in recent months. Analysts currently rate Roivant Sciences as a "Moderate Buy" with a consensus price target of $25.19, as the stock trades near $22.23 with a market capitalization of $15.46 billion.
Dec 25, 2025 • Simply Wall Street
BULLISH
Reassessing Roivant Sciences (ROIV) Valuation After Pipeline Progress, NDA Timelines and Genevant Litigation Updates
Roivant Sciences (ROIV) has seen significant pipeline momentum, with tightened timelines for key programs and an 86.26% YTD share price return. Despite trading at a premium to the US biotech industry on a price-to-book basis, the company is considered 12.2% undervalued by Simply Wall St's narrative, with a fair value of $25.64 against its current price of $22.50. This valuation hinges on future earnings from a potential $10 billion+ peak sales portfolio and ongoing business development activities, though risks like trial setbacks or unfavorable litigation outcomes exist.
Dec 24, 2025 • MarketBeat
SOMEWHAT-BULLISH
Voya Investment Management LLC Grows Stock Position in Roivant Sciences Ltd. $ROIV
Voya Investment Management LLC significantly increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 1,076.2% in the third quarter, now owning 497,823 shares valued at approximately $7.53 million. This increase comes alongside significant insider selling, with Director Daniel Allen Gold selling 777,332 shares for $17.93 million. Analyst sentiment for Roivant Sciences remains largely positive, holding a "Moderate Buy" consensus with an average price target of $25.19.